FOLH1 and prostate carcinoma: As target for our model system, we chose the prostate-specific membrane antigen (PSMA or glutamate carboxypeptidase II (EC 3.4.17.21)) [40] as it is often overexpressed in human prostate carcinoma (PCa) and thus of special clinical relevance).